ABBV vs ENSG
AbbVie vs Ensign Group — AI-powered side-by-side comparison
| Metric | ABBV | ENSG |
|---|
| AI Score |
69
|
68
|
| Price |
$249.34
|
$181.61
|
| P/E Ratio |
70.28×
|
27.65×
|
| ROE |
-129.2%
|
15.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
71.5%
|
14.1%
|
| Debt / Equity |
-11.93×
|
0.92×
|
| Dividend Yield |
2.7%
|
0.1%
|
| RSI (14) |
48.9
|
61.1
|
| Beta |
0.28
|
0.694
|
| Expected Upside |
—
|
+6.6%
|
AI Committee View
Current Innellis committee reasoning for ABBV versus ENSG.
ABBV leads by 1 points.
ABBV scores 69/100 (Buy) versus ENSG at 68/100 (Buy).
ABBV Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.20 across 84 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
ENSG Committee View
83% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock. The main limiting factor is p/e of 28.0 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 16.5% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 28.0 is moderate-to-rich — Value
- Price-to-book of 4.5x prices in significant intangible value — Value